Biphasic insulin aspart 30: Literature review of adverse events associated with treatment

The flexible and convenient treatmentregimen offered by BIAsp 30, together with its ability to improve postprandial glucose control, is associated with a safety profile comparable to that of BHI 30 and NPH insulin, with a lower risk of major and nocturnal hypoglycemic events.